Openbookopenbook
Equity
XOMA Corp(XOMA)
USD --+0.00%
Reward37Moderate
Risk65Medium-High
📊75%Data
Strong 46% profit margin · Revenue growing 30% YoY
XOMA
+0.0 · +0.00%
USD · NASDAQ
XOMA Corp | Healthcare
Capital Destroyer
Market Cap:316.14M
ℹ️
Reward Rating
37
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
65
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on XOMA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $65.75.

What is XOMA Corp?

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.

XOMA · Verdict

Limited reward · elevated risk

XOMA has limited near-term tailwinds — growth and cash flow weigh on the model output.

Based on 88% data coverage

XOMA · Verdict

What’s working & what to watch

Watchouts 5

  • Growth28/100

    Revenue -9.3% CAGR

  • Cash flow29/100

    -48% free-cash-flow margin

  • Balance sheet30/100

    Current ratio 5.15

  • Valuation35/100

    P/E 40.0×

  • Profitability41/100

    -49% net margin · 22% ROE

Model-based scoring. For information only — not financial advice.

What is XOMA Corp?

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 316.14M, and a P/E ratio of 34.0x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (37)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap316.14M
P/E Ratio34.04
Dividend YieldN/A
52 Week High39.92
52 Week Low18.35
Last AnnualDecember
IPO Date4/5/1989
IncorporatedUSA
Shares Outstanding12M
No. of Employees13
IndustryBiotechnology
ExchangeNASDAQ
Beta0.859
CurrencyUSD
Websitewww.xoma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.